| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/22/2011 | US7892549 Treatment with anti-ErbB2 antibodies |
| 02/22/2011 | US7892547 Methods and compositions for administering therapeutic and diagnostic agents |
| 02/22/2011 | US7892531 Human serum albumin(HSA); solubilized in low-ionic-strength buffer with specified ph; glycine, aspartic acid, sodium succinate, trehalose; binds with receptors |
| 02/22/2011 | CA2601515C Compounds having immunomodulator activity |
| 02/22/2011 | CA2565096C Method for the production of trans- or cis-diammoniumdichlorodihydroxoplatinum(iv) and the use thereof for the production of pharmaceutical agent |
| 02/22/2011 | CA2554195C Peptide originating in epidermal growth factor receptor (egfr) |
| 02/22/2011 | CA2476296C Amino-derivatives as inhibitors of histone deacetylase |
| 02/22/2011 | CA2474823C Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| 02/22/2011 | CA2468133C Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 02/22/2011 | CA2463968C Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
| 02/22/2011 | CA2459857C Combinatorial type controlled release drug delivery device |
| 02/22/2011 | CA2435503C Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| 02/22/2011 | CA2423833C Viruses targeted to hypoxic cells and tissues |
| 02/22/2011 | CA2411818C Cyclopentabenzofuran compounds and uses thereof |
| 02/22/2011 | CA2410193C Neuronal serine-threonine protein kinase |
| 02/22/2011 | CA2398163C Therapeutic morpholino-substituted compounds |
| 02/22/2011 | CA2359109C Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 02/22/2011 | CA2329772C Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| 02/22/2011 | CA2329181C 12,13-modified epothilone derivatives |
| 02/22/2011 | CA2319198C Substituted oxoazaheterocyclyl factor xa inhibitors |
| 02/22/2011 | CA2143491C A novel peptide related to human programmed cell death and dna encoding it |
| 02/17/2011 | WO2011020090A2 Compositions and methods for treating cancer |
| 02/17/2011 | WO2011020033A2 Engineered proteins including mutant fibronectin domains |
| 02/17/2011 | WO2011019986A2 Processes for preparing pemetrexed |
| 02/17/2011 | WO2011019943A1 Method of promoting apoptosis and inhibiting metastasis |
| 02/17/2011 | WO2011019798A1 Methods and compositions for treating leukemia |
| 02/17/2011 | WO2011019782A1 Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists |
| 02/17/2011 | WO2011019780A1 Azaindazoles as btk kinase modulators and use thereof |
| 02/17/2011 | WO2011019636A2 Methods and compositions for the treatment of cancers and pathogenic infections |
| 02/17/2011 | WO2011019634A2 Aryl substituted sulfonamide compounds and their use as anticancer agents |
| 02/17/2011 | WO2011019630A2 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
| 02/17/2011 | WO2011019419A1 Carbohydrate-mediated tumor targeting |
| 02/17/2011 | WO2011019393A2 Class- and isoform-specific hdac inhibitors and uses thereof |
| 02/17/2011 | WO2011019323A1 Particulate hyaluronic acid formulations for cellular delivery of bioactive agents |
| 02/17/2011 | WO2011019123A1 Novel peptide and use thereof |
| 02/17/2011 | WO2011019090A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| 02/17/2011 | WO2011019089A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| 02/17/2011 | WO2011019065A1 Tumor angiogenesis inhibitor |
| 02/17/2011 | WO2011019060A1 Hedgehog signal inhibitor |
| 02/17/2011 | WO2011019023A1 Agent for ameliorating blood-brain barrier disorders |
| 02/17/2011 | WO2011018510A1 New macrolides and their use |
| 02/17/2011 | WO2011018506A1 miRNA COMPOUNDS FOR TREATMENT OF PROSTATE CARCINOMA |
| 02/17/2011 | WO2011018454A1 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| 02/17/2011 | WO2011018417A1 Inhibitors of jnk |
| 02/17/2011 | WO2011018225A1 Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
| 02/17/2011 | WO2011018224A1 Combination therapy of an afucosylated cd20 antibody with bendamustine |
| 02/17/2011 | WO2011017998A1 Gambogic acid cyclization analogues, preparation method and application thereof |
| 02/17/2011 | WO2011017809A1 Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer |
| 02/17/2011 | WO2010138171A9 Methods for cancer treatment using stem cells |
| 02/17/2011 | WO2010124004A3 Nanocarrier therapy for treating invasive tumors |
| 02/17/2011 | WO2010122109A9 Method for the treatment of acute myeloid leukemia |
| 02/17/2011 | WO2010118339A3 Formulations of indole-3-carbinol derived antitumor agents with increased oral bioavailability |
| 02/17/2011 | WO2010099003A3 Compositions and methods for visualizing and eliminating cancer stem cells |
| 02/17/2011 | WO2010096603A3 Cancer-targeting peptides and uses thereof in cancer therapy |
| 02/17/2011 | WO2010092260A3 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof |
| 02/17/2011 | WO2010087976A3 Anti-cancer protein-platinum conjugates |
| 02/17/2011 | WO2010046289A3 Blockers of light, ltalpha1beta2 and ltalpha2beta1 or their receptor ltbetar for the prevention and treatment of chronic hepatitis and other liver diseases |
| 02/17/2011 | WO2010014841A8 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
| 02/17/2011 | US20110041190 Novel chimeric proteins |
| 02/17/2011 | US20110040259 Method for allogeneic cell therapy |
| 02/17/2011 | US20110040161 Device for generating a detectable signal based upon concentration of at least one substance |
| 02/17/2011 | US20110039937 Novel process for the preparation of vorinostat |
| 02/17/2011 | US20110039921 Cephalomannine derivatives, their preparation, pharmaceutical composition and use thereof |
| 02/17/2011 | US20110039920 Inhibitors of ikk-beta serine-theronine protein kinase |
| 02/17/2011 | US20110039919 Pharmaceutical compositions for inhibiting angiogenesis |
| 02/17/2011 | US20110039915 IMMUNOSTIMULATORY siRNA MOLECULES |
| 02/17/2011 | US20110039912 Therapeutic Agent for Neuroblastoma Targeting ARID3b |
| 02/17/2011 | US20110039911 METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY |
| 02/17/2011 | US20110039909 Methods and materials for reducing gli2 expression |
| 02/17/2011 | US20110039880 Aryl substituted sulfonamide compounds and their use as anticancer agents |
| 02/17/2011 | US20110039874 Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity |
| 02/17/2011 | US20110039872 Deuterium-enriched capecitabine |
| 02/17/2011 | US20110039869 Composition for inhibiting the activity of inositol 1,4,5-triphosphate receptor subtype iii |
| 02/17/2011 | US20110039868 Inhibitors of bruton's tyrosine kinase |
| 02/17/2011 | US20110039863 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 02/17/2011 | US20110039862 Protease Inhibitors |
| 02/17/2011 | US20110039856 Polymorphs of a c-met/hgfr inhibitor |
| 02/17/2011 | US20110039850 Leukemia Treatment |
| 02/17/2011 | US20110039845 2-aminoquinazoline derivative |
| 02/17/2011 | US20110039844 6-7,dialkoxy quinazoline derivatives useful for treatment of cancer related disorders |
| 02/17/2011 | US20110039840 Spirocyclic derivatives as histone deacetylase inhibitors |
| 02/17/2011 | US20110039839 Cyanopyrroles |
| 02/17/2011 | US20110039838 Pyrrolotriazine compounds as kinase inhibitors |
| 02/17/2011 | US20110039835 Substituted arylamide diazepinopyrimidone derivatives |
| 02/17/2011 | US20110039831 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| 02/17/2011 | US20110039828 Tetrahydroquinoline derivatives and a process for preparing the same |
| 02/17/2011 | US20110039827 Substituted hydroxamic acids and uses thereof |
| 02/17/2011 | US20110039826 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
| 02/17/2011 | US20110039824 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| 02/17/2011 | US20110039820 Lactam compounds useful as protein kinase inhibitors |
| 02/17/2011 | US20110039819 Substituted phenoxybenzamides |
| 02/17/2011 | US20110039815 Macrocyclic metal complexes for their use as anticancer agents |
| 02/17/2011 | US20110039800 Prolonged release bioadhesive therapeutic systems |
| 02/17/2011 | US20110039796 Natural Composition for Anti-Angiogenesis and Anti-Obesity |
| 02/17/2011 | US20110039789 Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer |
| 02/17/2011 | US20110039788 Compositions, methods and kits for detecting and treating cancer |
| 02/17/2011 | US20110039786 Metastin derivative and use thereof |
| 02/17/2011 | US20110039785 Polypeptide-nucleic acid conjugates and uses thereof |
| 02/17/2011 | US20110039779 Igf-1r binding proteins and antagonists |
| 02/17/2011 | US20110039778 Peptide Synthesis |